Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dBCG-Tokyo
- Development stage
- Preclinical
- Lead developer
- The University of Texas Medical Branch
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravesical, Inhalation
01
Overview
dBCG-Tokyo is a selectively delipidated formulation of the Mycobacterium bovis BCG Tokyo-172 strain. It is being developed as an improved immunotherapeutic agent for the treatment of non-muscle invasive bladder cancer (NMIBC) and as a potential vaccine for tuberculosis. The delipidation process involves the removal of specific surface lipids, such as phthiocerol dimycocerosates (PDIM) and phenolic glycolipids (PGL), which are associated with excessive inflammatory responses and tissue damage. By removing these components, dBCG-Tokyo aims to provide a more tolerable alternative to standard BCG therapy, reducing the incidence of BCG-intolerance while maintaining the ability to stimulate a robust antitumor immune response through the activation of innate immune pathways and recruitment of effector cells.
- Other names
- delipidated BCG-Tokyodelipidated Mycobacterium bovis BCG Tokyo strain
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on dBCG-Tokyo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dBCG-Tokyo.